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Abstract
Background: Information on cost-effectiveness of interventions to treat schizophrenia can assist health policy
decision making, particularly given the lack of health resources in developing countries like Thailand. This study
aims to determine the optimal treatment package, including drug and non-drug interventions, for schizophrenia in
Thailand.
Methods: A Markov model was used to evaluate the cost-effectiveness of typical antipsychotics, generic
risperidone, olanzapine, clozapine and family interventions. Health outcomes were measured in disability adjusted
life years. We evaluated intervention benefit by estimating a change in disease severity, taking into account
potential side effects. Intervention costs included outpatient treatment costs, hospitalization costs as well as time
and travel costs of patients and families. Uncertainty was evaluated using Monte Carlo simulation. A sensitivity
analysis of the expected range cost of generic risperidone was undertaken.
Results: Generic risperidone is more cost-effective than typicals if it can be produced for less than 10 baht per 2
mg tablet. Risperidone was the cheapest treatment with higher drug costs offset by lower hospital costs in
comparison to typicals. The most cost-effective combination of treatments was a combination of risperidone
(dominant intervention). Adding family intervention has an incremental cost-effectiveness ratio of 1,900 baht/DALY
with a 100% probability of a result less than a threshold for very cost-effective interventions of one times GDP or
110,000 baht per DALY. Treating the most severe one third of patients with clozapine instead of risperidone had
an incremental cost-effectiveness ratio of 320,000 baht/DALY with just over 50% probability of a result below three
times GDP per capita.
Conclusions: There are good economic arguments to recommend generic risperidone as first line treatment in
combination with family intervention. As the uncertainty interval indicates the addition of clozapine may be
dominated and there are serious side effects, treating severe patients with clozapine is advisable only for patients
who do not respond to risperidone and only in the presence of a stricter side effect monitoring system than
currently exists.
Background
Schizophrenia generally begins in early adulthood and
causes long term mental and physical impairment [1]. It
has a significant impact on individuals, families and
countries in terms of both health and economic loss. In
the 1999 Thai Burden of Disease and Injury study, schi-
zophrenia was responsible for 5% of all non-fatal health
loss measured in years lived with disability [2]. The
direct health care costs of schizophrenia account for
between 1% and 3% of total national health care expen-
diture worldwide [3-5]. Indirect costs related to lost pro-
ductivity are estimated to be higher or at least
equivalent to direct costs, in the range of 1 to 7 times
the direct costs [3,5-7]. The evidence, however, indicates
that Asian countries have a larger proportion of indirect
c o s t s( 8 7 %i nT a i w a n ,8 3 %i nK o r e a ,a n d6 3 %i nI n d i a )
[5,8,9] than those reported in Western countries (47%
to 70%) [3].
Thailand has limited health resources for mental dis-
orders, including schizophrenia. The government
devoted only 3.0% of health expenditure to mental
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sion makers have access to cost-effectiveness informa-
tion to prioritise allocation of resources within their
budget constraints.
Medications are the standard treatment to control
acute psychotic symptoms of schizophrenia. The newer
‘atypical’ antipsychotics have a similar effect on psycho-
tic symptoms as first-generation ‘typical’ antipsychotics
but cause different side effects and are much more
expensive [11-13]. The key problems with using medica-
tions alone are poor adherence and a partial improve-
ment in functional outcomes only [14]. A combination
of drug and non-drug interventions is commonly
recommended [15-17].
To our knowledge, there are no cost-effectiveness stu-
dies indicating what should be the first and second line
drug treatments in Thailand. This study aims to provide
policy makers with evidence on the optimal package of
drug and non-drug interventions for schizophrenia. We
undertook the current study as part of the Setting Prio-
rities using Information on Cost-Effectiveness (SPICE)
project which aimed to provide comparable cost-effec-
tiveness results across various disease areas to assist pol-
icy makers in priority setting decision making.
Methods
We selected interventions for analysis based on: a) effi-
cacy and/or effectiveness in published literature; b)
availability of evidence on clinical effectiveness, resource
utilization and costs; c) feasibility of implementation in
Thailand based on discussions with 10 local mental
health experts; and d) relevance to current policy-mak-
ing. Four drug interventions (typicals, risperidone, olan-
zapine and clozapine) and family interventions were
chosen for analysis. The comparator was a hypothetical
‘do nothing’ scenario using generalized cost-effective-
ness. This required a back-calculation from current
practice to the ‘partial null’,i . e .ah y p o t h e t i c a ls c e n a r i o
where we removed the effect of all currently implemen-
ted interventions [18,19]. An ‘intervention pathway’ was
calculated to determine the most cost-effective mix of
interventions.
Our study design was cost-effectiveness analysis using
a Markov model with cycles of one year. Patients with
schizophrenia in Thailand in the year 2005 were the tar-
get population. Each year patients could remain alive
with schizophrenia, recover or die from disease-related
or other causes (Figure 1). To reflect the chronic course
of schizophrenia, costs and effects were assessed until
age 80 or death. The annual transition probabilities
were based on local and overseas data (See Additional
file 1: Transition probability estimates).
The model was analyzed from a government costing
perspective. Our survey showed that 75% of patients
with schizophrenia used the universal coverage health
care system [20]. However, because schizophrenia has
significant impacts outside the health sector [1,3], we
also considered costs to patients and families (time and
travel costs). Discounting at 3% was applied to both
costs and benefits to be consistent with the study of
Burden of Disease in Thailand and in line with recom-
mendations from the Panel on Cost-Effectiveness in
Health and Medicine [2,21]. Our model was constructed
using Microsoft Excel.
Health effect estimations
Health outcomes from the drug and non-drug interven-
tions were measured in disability-adjusted life years
(DALYs) averted using identical methods. Intervention
effect size was measured as a change in disability weight
(DW) using a method described by Magnus et al [22] to
translate pooled effect sizes from the international litera-
t u r ei n t oac h a n g ei nD W .T oc o m b i n ee f f e c ts i z e s ,
Hedges’ g test was applied to determine the mean differ-
ence in standard deviation units including an adjustment
to correct for small sample sizes [23]. Because the psy-
chiatric literature usually reports efficacy measures
based on different psychometric scales [24], we calcu-
lated the effect sizes based on the Brief Psychiatric Rat-
ing Scale (BPRS) and the Positive and Negative
Syndrome Scale (PANSS) in our meta-analyses since
they are the most common scales for scoring psychiatric
symptoms. Our analyses relied heavily on the informa-
tion on intervention effects from Cochrane systematic
reviews [25-30]. The standardized effect sizes were then
pooled using the random effects meta-analysis method
to deal with variation around some overall average treat-
ment effect [23]. The method used in the Australian
Assessing Cost Effectiveness - Mental Health (ACE-
MH) project [22,24] to transfer the pooled effect sizes
into a change in disability weight was adjusted to
include the spread of the Brief Psychiatric Rating Scale-
Expanded (BPRS-E) scores from our survey, a cross-sec-
tional descriptive study including 307 people with schi-
zophrenia in Thailand (279 outpatients and 28
inpatients) [20,31]. We mapped each BPRS-E score
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Figure 1 Health state diagram.
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the Dutch lowest and highest DWs for schizophrenia
(0.21-0.98) using the methods developed by the ACE-
MH Study [24,32]. Note that the lowest disability weight
for schizophrenia still means a substantial loss of health
reflecting the disability associated with a stigmatized ill-
ness as well as some residual symptoms. Across the sur-
vey sample we calculated the standard deviation of the
BPRS scores and estimated the average health loss (in
disability weight) associated with a 1 SD change in
severity [20]. As the effect sizes for the impact of inter-
ventions are expressed in standard deviation units, we
could then impute the average change in disability
weight given an effect size for each intervention. The
impact of a change in extrapyramidal (EPS) adverse
effect was estimated separately and transferred into an
additional change in DW. We borrowed data on the
proportions of patients with moderate and severe EPS
due to typicals (25%) and atypicals (13%), as well as the
DW of each severity level, i.e. 0.422 and 0.453 for mod-
erate and severe EPS, respectively from the Australian
study [22] to calculate the DW change due to less EPS
on atypicals. Due to lack of data we had to assume that
all the atypicals induced EPS equally.
Apart from accounting for the EPS side effects in the
change in DW, we also estimated the mortality and
morbidity risks associated with the average weight gain
associated with each drug using the potential impact
fraction RiskIntegral add-in for Excel (http://www.epi-
gear.com). The benefit of preventing suicide was taken
into account for clozapine, the only antipsychotic drug
with evidence of this effect [33]. The weighted average
relative risk of suicide for people taking clozapine was
0.53, calculated using data from studies by Munro [34]
and Harris [35]. Table 1 shows the input parameters
used to estimate intervention benefits.
Due to the absence of Thai data on adherence to drug
treatment for schizophrenia, we assumed adherence of
47% (« 7.4%) from a review study by Lacro et.al [36]. A
study on depression treatment in Thailand found adher-
ence of 41%, indicating a similar level of adherence
within the mental health system [37]. We applied this
rate for both people receiving atypical and typical anti-
psychotics [38,39]. We provide further details of health
effect estimation via the online document (See Addi-
tional file 1: Health effect estimations)
Cost estimations
The cost analyses comprise of: a) intervention cost; b)
medical costs for treating or preventing side effects; c) cost
of hospitalization; and d) time and travel cost of patients
and families. All costs were adjusted to 2005 using the
Consumer Price Index (CPI) based on data from the Bank
of Thailand website (http://www.bot.or.th).
We estimated the annual drug cost for each of the
antipsychotics by combining the unit cost for a standard
daily dose with the costs of drug administration (i.e.
outpatient visits). Costs of benzhexol, an anticholinergic
drug that treats EPS side effects were also included. We
separately measured costs of regular blood tests to pre-
vent the fatal adverse effect of clozapine, agranulocytosis
[40]. We used a 27% hospitalization rate among patients
on typicals based on local data [20] while adopting the
relative reduction in hospitalization rates in patients tak-
ing atypicals from Leucht et al. [41]. According to the
Cochrane review study, we assumed that by comparison
with no treatment typicals reduce the hospitalization
rate by 50% [42].
The costs of family interventions mainly consisted of
start-up costs (development and training) and ongoing
costs (services, supplies, travel and salary). We assumed
that the family intervention protocol would be prepared
by 2 specialists employed by the project for 100 hours
each and a training program would be conducted for a
group of clinicians from all 17 psychiatric hospital
across Thailand. One psychiatrist and 20 psychiatric
nurses from each hospital would be trained. The family
intervention program would consist of 10 weekly 2-hr
sessions by a psychiatric nurse [43]. We assumed that
each session would have 16 participants (8 patients and
8 family carers). As there is no information on the
longer term outcomes of family interventions, we
assumed after expert consultation that 2 booster ses-
sions to patients and families every year, would enable
Table 1 Input parameters for estimation of health outcome for drug and non-drug interventions compared to ‘do
nothing’
Intervention DW change (95% CI) RR of suicide Weight change (kg) proportion of patients with moderate and high EPS
Typicals -0.069 (-0.032, -0.101) 1 1.42 25%
Risperidone -0.085 (-0.050, -0.116) 1 2.10 13%
Olanzapine -0.095 (-0.060, -0.127) 1 4.15 13%
Clozapine -0.099 (-0.067, -0.128) 0.54 4.45 13%
Family intervention
1 -0.076 (-0.064, -0.085) 1 - -
Data source: RR of suicide [34,35]; Weight change [56] and Proportion of patients with moderate and high EPS [22,57]
1 Additional benefit to drug interventions
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lifetime.
Time cost was assumed to be 25% of personal income
per capita in Thailand in 2005 (http://www.nesdb.go.th)
and travel costs of patient and families were computed
using patient-reported data from our survey [20]. The
cost parameters, values and data sources are described
in the online supporting document (See Additional file
1: Assessment of intervention cost).
Sensitivity analysis
One way sensitivity analysis was undertaken for (a)
intervention costs including and excluding time and tra-
vel costs of patients and families; and (b) varying costs
of risperidone. Generic risperidone is not yet available
in Thailand. However, the Royal College of Psychiatrists
of Thailand has urged the Government Pharmaceutical
Organization to produce a generic version of risperidone
following the expiration of its patent and it is currently
in the process of Food and Drug Administration
approval [44]. In this sensitivity analysis we modelled
risperidone prices ranging from 4 baht (expected generic
price [44]) to 50 baht. We compared risperidone to typi-
cals in this sensitivity analysis.
Probabilistic sensitivity analysis using Monte Carlo
simulation was undertaken using an Excel add-in Ersatz
(http://www.epigear.com). The uncertainties in all values
were considered simultaneously using appropriate distri-
butions and relevant parameters. Additional online
information provides the details of input parameters,
distributions and data sources used for uncertainty ana-
lysis (See Additional file 1: Uncertainty parameters and
distributions.
Additional policy-relevant criteria
While the initial results were based on cost-effectiveness
analysis, broader aspects which may be important in
terms of policy, known as “second filter” criteria, were
also considered. In Australian ‘Assessing Cost-Effective-
ness’ studies ‘strength of evidence’, ‘equity’, ‘feasibility’,
‘acceptability’ and sustainability have been considered
[45]. Our expert advisory group and the steering
committee of the SPICE project played an important
role in applying these second filter criteria and formulat-
ing policy recommendations.
Results
Atypical antyipsychotics were not significantly more
effective than typicals in reducing the severity of disease
(Tables 1 and 2). Clozapine had an additional benefit of
preventing suicide but greater health loss from weight
gain than the other drugs (Table 2). Family intervention
had additional health benefits when combined with drug
treatment.
A tac o s to f4b a h tp e r2m gt a b l e t ,g e n e r i cr i s p e r i -
done would be the preferred drug treatment due to
lower hospital costs despite higher drug costs (Table
3). While all atypicals have lower hospital costs than
typicals, the drug cost of risperidone, only, was offset
by hospital saving. The annual cost of clozapine treat-
ment per individual was about twice that for typicals
or risperidone, mostly because of the higher cost of
monitoring side effects and the associated time costs
of patients. Olanzapine was the most costly drug,
approximately 7 times higher than typicals and risper-
idone. Giving risperidone with family interventions
was more expensive than risperidone alone by 4,000
baht in the first year due to higher patient and family
costs.
By comparison with ‘do nothing’, most of the selected
interventions, with the exception of clozapine and olan-
zapine, were cost-saving (Table 4). The cost-effective-
ness ratio of clozapine (12,000 baht/DALY averted) was
below Thailand GDP per capita of 110,000 baht which
is considered the threshold for very cost-effective health
interventions (http://www.dcp2.org). When we included
costs of patient and family time in the analyses, all of
the interventions were no longer dominant but their
cost-effectiveness ratios (except for clozapine and olan-
zapine) still fell well below the threshold of 110,000
baht. Olanzapine (1,000,000 baht/DALY averted) has an
unfavourable cost-effectiveness ratio due to its high cost
for at most only a small additional benefit over other
drug treatments.
Table 2 Health effects of typical and atypical antipsychotic compared to ‘do nothing’ over the lifetime people with
schizophrenia in the 2005 Thai population
Intervention DALYs averted
Severity of disease Weight gain Mortality due to suicide Total (95% CI)
Typicals 450,000 -5,800 - 440,000 (290,000, 610,000)
Risperidone 540,000 -9,100 - 530,000 (370,000, 710,000)
Olanzapine 580,000 -14,000 - 570,000 (390,000, 770,000)
Clozapine 620,000 -15,000 20,000 630,000 (440,000, 830,000)
FI+Risperidone
1 920,000 -9,100 - 910,000 (640,000, 1,100,000)
1 FI = family intervention; results are for risperidone together with FI.
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eric risperidone, assuming the cost is 4 baht per 2 mg
tablet (Figure 2 and Table 5). The next step would be to
add family interventions to risperidone with significant
health gain at a small net cost (ICER 1,900 baht/DALY;
95%CI: “dominant”, 18,000; 100% probability of a result
below the one times GDP per capita). Providing cloza-
pine instead of risperidone to the most severe one-third
of patients has an ICER of 320,000 baht/DALY (95% CI:
26,000, “dominated"; 51% probability of a result below
the three times GDP per capita threshold of 330,000
baht/DALY for cost-effective interventions). We
assumed that patients who had a score greater than 40
on the BPRS (this would include about one-third of
patients in our survey) would be eligible for clozapine
[20,31]. “Dominated” denotes an intervention more
costly and less effective than the comparator, while
“dominant” means the intervention is more effective and
less costly than the comparator.
Analysis of generic risperidone was based on an
“expected cost”. The actual cost for generic risperidone
could have a significant impact on the cost-effectiveness,
so we examined potential values in a one-way sensitivity
analysis (Figure 3). If generic risperidone costs less than
10 baht per 2 mg tablet, it is dominant over typicals. Up
to a cost of 19 baht (95% uncertainty interval 15-25
baht) replacing typicals by risperidone would still be
considered a very cost-effective intervention against a
threshold of 110,000 baht.
Based on the CEA results, the recommended interven-
tion package would be the combination between risperi-
done, clozapine and family interventions. Providing
clozapine for highly severe patients cannot be recom-
mended until it is ensured that its serious side effect of
agranulocytosis is prevented: patients receive periodic
blood test during this treatment (Table 6).
Discussion
The three main findings from this study are (a) generic
risperidone should be used as the first line drug treat-
ment for schizophrenia if the cost is less than 10 baht
per 2 mg tablet; (b) combining risperidone with family
interventions will substantially increase health gain with
lower hospitalization cost; and (c) clozapine could be a
second line medication for patients with high severity
who fail to respond to risperidone.
The key recommendation of this study is that risper-
idone should be included in the national drug list
while olanzapine should not (Table 6). Clozapine
should be reserved for severe patients who do not
Table 3 Costs of interventions analyzed per individual receiving the intervention in the first year
Cost (baht/year)
Drug intervention Intervention Side effects Hospitalization Time cost Total (95% CI)
Typicals 3,300 400 8,100 1,300 13,000 (11,000, 15,000)
Risperidone 4,300 250 5,200 1,300 11,000 (9,500, 13,000)
Olanzapine 81,000 160 5,200 1,300 88,000 (84,000, 93,000)
Clozapine
1 4,600 3,800 5,200 6,900 21,000 (19,000, 22,000)
FI
2+Risperidone 6,300 - 4,500 4,400 15,000 (13,000, 17,000)
Notes: all estimates are rounded to two significant digits
1 Clozapine is associated with rare but serious blood disorders and hence frequent blood tests are required.
2 FI = family intervention; cost of FI shown is that of the more intensive first year.
Table 4 Average cost-effectiveness ratios of interventions
Intervention Average cost-effectiveness ratio
Tx
1 Tx+Hosp
2 Tx+Time
3 Total
Typical 64,000 Dominant
4 87,000 Dominant
Risperidone 66,000 Dominant 85,000 Dominant
Olanzapine 1,100,000 980,000 1,100,000 1,000,000
(730,000; 1,400,000)
Clozapine 80,000 Dominant 130,000 12,000 (Dominant; 38,000)
FI
5 + Risperidone 42,000 Dominant 57,000 Dominant
Risperidone (2/3) & Clozapine (1/3)
6 + FI 45,000 Dominant 67,000 Dominant
1 Tx = average cost-effectiveness ratio taking into account treatment costs only
2 Tx+Hosp = average cost-effectiveness ratio taking into account treatment and hospital costs
3 Tx+Time = average cost-effectiveness ratio taking into account treatment and time and travel costs
4 Dominant = more effective and less costly than comparator \
5 FI = family intervention
6 Giving clozapine to one-third of patients with high severity
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in treatment-resistant schizophrenia and in preventing
suicidal behaviour [33,46]. However, the poor compli-
ance with the Clozapine Patient Monitoring Service
p r o g r a mi nT h a i l a n d[ 4 7 ]m e a n st h a tc l o z a p i n ec a n n o t
be recommended until monitoring has improved.
T h es t i g m ao fs c h i z o p h r e n i ac o u l db eas i g n i f i c a n t
barrier to family interventions [48]. More importantly,
due to a lack of mental health resources and high travel
costs, poor households and people living in rural areas
may have limited access. A new stream of long term
government funding would be required to provide
family interventions across the country and make these
services accessible long-term.
This study has several limita t i o n s .F i r s t ,t h es t u d i e s
included in our meta-analyses were generally from
Western countries not Thailand or other Asian coun-
tries. Second, the course of disease varies considerably
between patients. Modelling the average cost and
impact on the average case of disease could lead to
erroneous conclusions [49]. The alternative is to use a
microsimulation approach; however, that would require
more clinical and epidemiological information on indi-
viduals than we had available. Third, the methods used
for translating the effect sizes into a change in DW
need the assumption that the effect sizes from trials
can be directly applied to general health status esti-
mated using a generic measurement. Normally, generic
measurements are less relevant to schizophrenia’s
symptoms by comparison with specific ones as BPRS
used in this study. However, this is the only method
allowing us to clarify DWs in patients with different
treatments. An advantage of using this method is that
we could include Thai data on the individual patients
into the analysis. We would content that it is not
necessarily so that departure from the assumed linear
relationship between symptom change and disability
change would lead to over-estimation of health bene-
fits in DALYs. Fourth, the assumption that patients
remain on the same treatment throughout the course
of their illness is in contrast to the common clinical
practice of switching patients from one treatment to
another treatment based on individual medication
responses [50]. However, a large double-blinded rando-
mized clinical trial in the US suggested no difference
in rates of improvement between patients with atypical
antipsychotics switching to a new medication and
patients staying on their initial treatment [51]. Finally,
we have not incorporated the costs of treating diseases
related to increased body weight due to unavailability
of local disease costing data. Because there is only a
small difference in weight gain between typicals and
risperidone, this limitation is unlikely to affect the
findings.
Our study also has several maj o rs t r e n g t h s .F i r s t ,t h e
information used for assessing costs and effectiveness of
each intervention is documented and transparent, and
from Thai sources wherever possible. Second, to our
knowledge, there is no previous study including time
and travel costs in the cost estimations. Our findings
show that these are a significant burden on patients and
Figure 2 Ideal mix of schizophrenia interventions based on
their cost-effectiveness ratio in Thailand.
Table 5 Incremental cost-effectiveness ratios of optimal package of interventions
Intervention(s) Incremental cost-effectiveness ratio Probability of ICER below
1 × GDP 3 × GDP
Risperidone Dominant 100% 100%
Add Family intervention 1,900 100% 100%
Add clozapine to most severe one third replacing risperidone 320,000 38% 51%
0 
Figure 3 Incremental cost effectiveness analysis results using
the range of risperidone costs by comparison with typicals.
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tions. Third, we clearly address the issue of uncertainty
in the data, presenting our results as a range within
which the value is expected to fall. Fourth, we have had
regular contact with local policy makers over the five-
year span of our work. As a result of this, the food and
drug administration in Thailand has already allocated 40
million baht to add generic risperidone to the national
essential drug list.
This is the first study of its kind in Thailand. Studies
elsewhere have modeled cost-effectiveness of different
atypical antipsychotics, with fewer studies addressing
both drug and non-drug interventions. Our results are
in line with previous research. A study conducted in
Slovenia which measured effectiveness as the percentage
of patients in remission found that risperidone was
more cost-effective than haloperidone and olanzapine
for schizophrenia [52]. Studies in Canada, Brazil and
Australia consistently found that using risperidone
rather than olanzapine would reduce the medical costs
of schizophrenia [22,53,54]. In contrast, a number of
studies using the method developed by the WHO-
CHOICE project suggested using typical antipsychotics
in combination with psychosocial interventions [55].
However, the authors discussed that if generic forms of
atypical medication would become available, the findings
could change [55] as our sensitivity analysis indicates.
Costs associated with drug treatments are a major driver
of the results of cost-effectiveness analysis and limit the
applicability of our conclusions to other countries.
A combination of psychosocial interventions and med-
ications has been highly recommended as a successful
treatment package for schizophrenia [16]. Our results
confirm that this package not only provides more health
gain to patients, but also could help the government to
reduce hospitalization cost by as much as 40% com-
pared to typicals (Table 3). The hospitalization cost is
generally considered to be the most expensive compo-
nent of direct costs [3,5,8,9].
Conclusions
The cost of medications is the most important factor in
the cost-effectiveness of antipsychotic interventions for
schizophrenia. Atypicals are more cost-effective than
typicals if their generic versions can be produced at a
cost level achieved for many other generic medications
in Thailand. Family intervention is an additional cost-
effective option to help not only improve disease sever-
ity, but also reduce hospitalizations thus lessening the
economic burden on the government.
Table 6 Considerations of additional policy-relevant criteria
Criteria Intervention package for schizophrenia
Level of
evidence:
￿ We have relied heavily on evidence provided in Cochrane systematic reviews and used their inclusion criteria when adding more
recent trials.
￿ There is sufficient data for drug interventions while few trials are available for psychosocial intervention. Most trials were
conducted in Western countries and doubts remain about the applicability of these findings to Thailand. A number of further
methodological problems were identified in this trial literature: the varying choice of comparator in the evaluation of psychosocial
interventions; use of high doses of typicals as comparator in trials of newer generation drugs; potential publication bias; and short
durations of follow-up
Equity: ￿ Generic risperidone is recommended as the first line drug treatment and should be included in the national essential drug list so
that it can be prescribed equitably to all Thai patients.
￿ Lack of mental health resources and higher travel costs for patients and families may make family interventions less available or
affordable in rural and remote areas. Poor households may have less access to this intervention.
Feasibility: ￿ Increased prescribing of clozapine in Thailand would be advisable only if health care units can maintain monthly blood testing.
This would require additional support from the government to help patients and families with the travel cost.
￿ The availability of mental health resources psychiatric nurses or psychologists, training programs and accessibility of health care
units are of concern.
￿ Maintaining the benefit of family interventions annually is possibly more difficult than doing it in the first year for a number of
reasons: (a) the patients migrate to other areas; (b) the families have no time available during the program period; (c) lack of long
term budget to support the program; and (d) the trained nurses change workplace or quit the careers.
Acceptability: ￿ The major effectiveness measurement of this study is symptom reduction based on clinical perspectives. In fact, the patient and
families might have different views. This measurement by clinicians may be too limited from the point of view of patients and
families who are interested in general wellbeing and productivity gains, for example. However, recent studies [58-60] found that
psychiatric symptoms are the best independent predictors of these broader outcomes of schizophrenia (e.g. objective and
subjective quality of life and social skill functions).
￿ Some policy makers and clinicians may be reluctant to use clozapine due to its rare but fatal side effect. Although a recent long-
term follow-up study in Finland found a lower mortality rate among people with clozapine than those with other antipsychotics
[61], less intensive monitoring for those on clozapine treatment in Thailand than Finland means these low mortality rates are
unlikely to be achieved [47,61].
￿ Self-stigma of people with schizophrenia and their families could be an obstacle to involvement in a psychosocial intervention
program [48].
Sustainability: ￿ In order to maintain lifetime benefits due to family interventions, a long-term public funding is required from the government.
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Additional file 1: Estimations of transition probabilities, health
outcomes and intervention costs. 1) Transition probability
estimates - This file explains a Markov cohort model with 3 health
states: alive with schizophrenia, alive without schizophrenia and dead
due to suicide, increased body weight or other causes. 2) Health effect
estimations - This file describes measurement of the health benefit as a
change in severity of disease calculated as a change in disability weight.
Additionally, it provides details on estimation of the mortality and
morbidity risks associated with weight gain. 3) Uncertainty parameters
and distributions - This file gives information on uncertainty
parameters, distributions used and data sources. 4) Assessment of
intervention cost - This file gives details on cost estimates including
cost elements, cost value and data sources.
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